MedTrace Logo

Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia

NCT00965666 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-09-14

No results posted yet for this study

Summary

The purpose of this research study is to evaluate the safety of the drug Etanercept (Enbrel) and to determine if this drug can help in the treatment of early bone marrow failure in patients with Fanconi anemia.

Conditions

  • Fanconi Anemia

Interventions

DRUG

Etanercept

All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Stella M. Davies, MBBSPhd MRCP · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00965666 on ClinicalTrials.gov